This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Examining the Phase 3 Results for denifanstat for the treatment of moderate-to-severe acne from Sagimet's partner Ascletis
Ticker(s): SGMT, ASCLFWho's the expert?
- Private practice dermatologist
- Treats 10+ adolescent patients with moderate to severe plaque psoriasis annually
Interview GoalThis conversation will focus on the recent Phase 3 data on SGMT's Oral FASN inhibitors, denifanstat, which offers a novel mechanism of action for the potential treatment of moderate to severe acne.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
